Recombinant nonimmunogenic staphylokinase
Phase 3Protein / enzyme
Recombinant nonimmunogenic staphylokinase is one of 97 small molecule programs targeting Ischemia. It is currently in Phase 3.
3
Indications
3
Total Trials
1
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Recombinant nonimmunogenic staphylokinase
SSupergene, LLC
Phase 3
COVID-19 Vaccine
ModernaPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Activella
Eli LillyPreclinical
Benadryl
PParkedale
Preclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
DAS181
AAnsun Biopharma, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemia1 trial
COVID-191 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- SSupergene, LLC